Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.51 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018889 | 0.90 | BTK (0.54) | BTKBRAFTNNI3KEGFR | |
| SCHEMBL2019640 | 0.87 | BTK (0.48) | BTKBRAFTNNI3KEGFRABL1 | |
| SCHEMBL12492598 | 0.86 | BRAF (0.50) | BTKBRAFTNNI3KSCN9AEGFR | |
| SCHEMBL2019319 | 0.85 | BTK (0.60) | BTK | |
| SCHEMBL2020574 | 0.84 | BTK (0.48) | BTKBRAFTNNI3KSCN9AEGFR | |
| SCHEMBL2018946 | 0.83 | BTK (0.55) | BTKBRAFTNNI3KEGFR | |
| SCHEMBL2019641 | 0.82 | BTK (0.60) | BTKBRAFTNNI3KEGFR | |
| SCHEMBL2019287 | 0.80 | EGFR (0.59) | BTKBRAFTNNI3KEGFR | |
| SCHEMBL12635826 | 0.79 | BTK (0.56) | BTKBRAFTNNI3KEGFR | |
| SCHEMBL2019679 | 0.79 | EGFR (0.58) | BTKBRAFTNNI3KEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-102892768-A | Substituted pyrrolo-aminopyrimidine compounds | ARQULE INC | 2013-01-23 | — | — | CN | disclosed |
| EP-2519525-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | DPYD, TYMP, DHFR | BTK 1600/4885BRAF 470/4885TNNI3K 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.